Sudha Parasuraman

Sudha Parasuraman is an accomplished medical professional with extensive experience in leadership roles within the pharmaceutical and biotechnology sectors. Currently serving as a Board Director at Terray Therapeutics since May 2023, Sudha previously held the position of Chief Medical Officer at Ribon Therapeutics from August 2019 to July 2024. Additional experience includes roles as a Drug Development Consultant for various clients, interim CMO for Imara Inc, and Chief Medical Officer at X4 Pharmaceuticals. Sudha's background features significant positions at uniQure, Novartis Oncology, Millennium - The Takeda Oncology Company, and academic roles at Harvard Medical School and Boston Children's Hospital/Dana Farber Cancer Institute. Education was completed at the University of Madras, with early training at St. Jude Children's Research Hospital in Pediatric Hematology Oncology.